Nanobiotix (NASDAQ:NBTX) Shares Up 5% – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price was up 5% during mid-day trading on Thursday . The company traded as high as $23.68 and last traded at $23.6760. Approximately 33,646 shares were traded during mid-day trading, a decline of 7% from the average daily volume of 36,145 shares. The stock had previously closed at $22.54.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NBTX. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Finally, Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $11.00.

Nanobiotix Price Performance

The stock’s 50 day simple moving average is $21.68 and its two-hundred day simple moving average is $12.42.

Institutional Trading of Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. purchased a new stake in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.